International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 143016 - 143016
Опубликована: Апрель 1, 2025
Язык: Английский
International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 143016 - 143016
Опубликована: Апрель 1, 2025
Язык: Английский
Colloids and Surfaces B Biointerfaces, Год журнала: 2024, Номер 245, С. 114285 - 114285
Опубликована: Сен. 30, 2024
Язык: Английский
Процитировано
7Biomedicine & Pharmacotherapy, Год журнала: 2024, Номер 177, С. 117118 - 117118
Опубликована: Июль 14, 2024
Hepatocellular carcinoma (HCC) is one of the most prevalent malignant tumors in contemporary era, representing a significant global health concern. Early HCC patients have mild symptoms or are asymptomatic, which promotes onset and progression disease. Moreover, advanced insensitive to chemotherapy, making traditional clinical treatment unable block cancer development. Sorafenib (SFB) first-line targeted drug for with anti-angiogenesis anti-tumor cell proliferation effects. However, efficacy SFB constrained by its off-target distribution, rapid metabolism, multi-drug resistance. In recent years, nanoparticles based on variety materials been demonstrated enhance targeting therapeutic against HCC. Concurrently, advent joint delivery systems has furnished crucial empirical evidence reversing This review will summarize application nanotechnology field over past five years. It focus research progress combined multiple modalities treatment.
Язык: Английский
Процитировано
6International Journal of Biological Macromolecules, Год журнала: 2025, Номер unknown, С. 143016 - 143016
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0